Third Harmonic halting non-THB335 research, reducing workforce by 50%
In parallel with THB335 Phase 2 readiness activities, Third Harmonic Bio (THRD) is initiating a process to identify opportunities to maximize ...
Third Harmonic Bio Initiates Strategic Review, Lays Off 50% Staff Citing Competitive Landscape
Third Harmonic Bio, Inc. (NASDAQ:THRD) revealed results from its Phase 1 single and multiple ascending dose (SAD/MAD) trial ...
Wall Street Journal26d
Third Harmonic Bio Inc.
1 Day THRD 1.94% DJIA 0.78% Russell 2K 0.40% Health Care/Life Sciences 1527.34% ...
Third Harmonic Bio announces Phase 1 clinical results for THB335
Third Harmonic Bio (THRD) announced results from its Phase 1 single and multiple ascending dose clinical trial of THB335 in healthy volunteers.
Nasdaq2y
Third Harmonic Bio, Inc. Common Stock (THRD) Institutional Holdings
Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...
Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate Strategic Update
THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU) Company initiating process to leverage balance sheet strength to maximize shareholder value ...